Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $39.25.

Several research firms have weighed in on STOK. Guggenheim initiated coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price target on the stock. Wolfe Research initiated coverage on Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price for the company. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a report on Monday, December 15th. Finally, Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Monday, January 5th.

Stoke Therapeutics Trading Down 1.1%

NASDAQ:STOK opened at $37.94 on Friday. The company has a market capitalization of $2.17 billion, a P/E ratio of 56.63 and a beta of 1.07. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $40.22. The firm has a fifty day simple moving average of $32.57 and a 200-day simple moving average of $29.41.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in Stoke Therapeutics by 1.2% in the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after purchasing an additional 354 shares during the last quarter. Strs Ohio lifted its holdings in shares of Stoke Therapeutics by 9.4% in the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after buying an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after buying an additional 658 shares during the period. Generali Investments Management Co LLC boosted its stake in shares of Stoke Therapeutics by 41.0% in the fourth quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after buying an additional 718 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics in the fourth quarter worth about $26,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.